

**Editor**

Josef S Smolen

**Associate Editors**

Trisan Barber  
Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiro Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 12.350

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2019 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 581** Time to change the primary outcome of lupus trials  
*F A Houssiau*

**Heroes and pillars of rheumatology**

- 583** Jan Gösta Waldenström and rheumatology  
*F A Wollheim*

**Rheumatoid arthritis**

- 586** Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up  
*P BM Poppelaars, L H D van Tuyl, M Boers*

- 590** *Prevotella copri* in individuals at risk for rheumatoid arthritis

*D Alpizar-Rodriguez, T R Lesker, A Gronow, B Gilbert, E Raemy, C Lamacchia, C Gabay, A Finckh, T Strowig*

- 594** *Porphyromonas gingivalis* experimentally induces periodontitis and an anti-CCP2-associated arthritis in the rat  
*G Courbon, M Rinaudo-Gaujous, V Blasco-Baque, I Auger, R Caire, L Mijola, L Vico, S Paul, H Marotte*

- 600** PTPN14 phosphatase and YAP promote TGF $\beta$  signalling in rheumatoid synoviocytes  
*A Bottini, D J Wu, R Ai, M Le Roux, B Bartok, M Bombardieri, K M Doody, V Zhang, C Sacchetti, M Zoccheddu, A Lonic, X Li, D L Boyle, D Hammaker, T-C Meng, L Liu, M Corr, S M Stanford, M Lewis, W Wang, G S Firestein, Y Khew-Goodall, C Pitzalis, N Bottini*

**Psoriatic arthritis**

- 610** Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate  
*L J J van Mens, H M de Jong, I Fluri, M T Nurmohamed, M G H van de Sande, M Kok, A W R van Kuijk, D Baeten*

**Juvenile arthritis**

- 617** Machine learning identifies an immunological pattern associated with multiple juvenile idiopathic arthritis subtypes  
*E Van Nieuwenhove, V Lagou, L Van Eyck, J Dooley, U Bodenhofer, C Roca, M Vandebergh, A Goris, S Humblet-Baron, C Wouters, A Liston*

**Systemic lupus erythematosus**

- 629** Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus  
*S Oon, M Huq, V Golder, P X Ong, E F Morand, M Nikpour*

- 634** Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus  
*S K Tedeschi, S R Johnson, D T Boumpas, D Daikh, T Dörner, B Diamond, S Jacobsen, D Jayne, D L Kamen, W J McCune, M Mosca, R Ramsey-Goldman, G Ruiz-Irastorza, M Schneider, M Urowitz, D Wofsy, J S Smolen, R P Naden, M Aringer, K H Costenbader*

**Sjögren's syndrome**

- 641** Treatment of primary Sjögren's syndrome with ivalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity  
*T Dörner, M G Posch, Y Li, O Petricoul, M Cabanski, J M Milojevic, E Kamphausen, M-A Valentin, C Simonett, L Mooney, A Hüser, H Gram, F D Wagner, S J Oliver*

**Systemic sclerosis**

- 648** Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort  
*W Wu, S Jordan, N Graf, J de Oliveira Pena, J Curram, Y Allanore, M Matucci-Cerinic, J E Pope, C P Denton, D Khanna, O Distler, EUSTAR Collaborators*

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>



Member since 2008

JMK0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

**Myositis**

- 657** [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis



*J B Lilleker, R Hodgson, M Roberts, K Herholz, J Howard, R Hinz, H Chinoy*

**Gout**

- 663** mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?

*N Vazirpanah, A Otrria, M van der Linden, C G K Wichers, M Schuiveling, E van Lochem, A Phipps-Green, T Merriman, M Zimmermann, M Jansen, T R D J Radstake, J C A Broen*

**Osteoarthritis**

- 672** Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis



*I S von Loga, A El-Turabi, L Jostins, J Miotla-Zarebska, J Mackay-Alderson, A Zeltins, I Parisi, M F Bachmann, T L Vincent*

- 676** Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis

*L Zhao, J Huang, Y Fan, J Li, T You, S He, G Xiao, D Chen*

**Epidemiology**

- 683** Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome

*H Westerlind, M Holmqvist, L Ljung, T Frisell, J Askeling*

- 688** Common mental disorders within chronic inflammatory disorders: a primary care database prospective investigation

*A Dregan, F Matcham, L Harber-Aschan, L Rayner, A Brailean, K Davis, S Hatch, C Pariente, D Armstrong, R Stewart, M Hotopf*

- 696** Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero

*J Mofors, H Eliasson, A Ambrosi, S Salomonsson, A Skog, M Fored, A Ekholm, G Bergman, S-E Sonesson, M Wahren-Herlenius*

**Letters**

- 704** Incidence of inflammatory polyarthritis in polymyalgia rheumatica: a population-based cohort study

*M Yates, J Kotecha, R A Watts, R Luben, K-T Khaw, A J MacGregor*

- 705** Serum IgG N-glycans act as novel serum biomarkers of ankylosing spondylitis



*J Wang, C Wang, Y Liang, H Pan, Z Jiang, Z Li, Y Li, L Xia, W Liu, X Zhang, Z Liu, M Jiang, J Liu, H Zhou, L Liu*

- 707** Normal vaginal microbiome in women with primary Sjögren's syndrome-associated vaginal dryness

*T A van der Meulen, J F van Nimwegen, H J M Harmsen, S C Liefers, K van der Tuuk, F G M Kroese, M J E Mourits, A Vissink, H Bootsma*

- 709** Neutrophils are not consistently activated by antineutrophil cytoplasmic antibodies in vitro



*R J Popat, M G Robson*

- 711** Role of linoleic acid in autoimmune disorders: a Mendelian randomisation study

*J V Zhao, C M Schooling*

- 713** Swimming against the stream: the fishbowl discussion method as an interactive tool for medical conferences: experiences from the 11th European Lupus Meeting

*J Mucke, H-J Anders, M Aringer, G Chehab, R Fischer-Betz, F Hiepe, H-M Lorenz, A Schwarting, C Specker, R E Voll, M Schneider*

**Electronic pages**

- e33** Lack of standardisation of ANA and implications for drug development and precision medicine

*M Mahler*

- e34** Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler

*D S Pisetsky, D M Spencer, P E Lipsky, B H Rovin*

- e35** 'A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-κB-mediated autoinflammatory disease'

*F Berteau, B Rouvière, A Nau, R Le Berre, G Sarabay, I Toutou, C de Moreuil*

- e36** Response to: 'A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF- $\kappa$ B-mediated autoinflammatory disease' by Aeschlimann *et al*  
*F A Aeschlimann, R M Laxer*
- e37** Postpartum breastfeeding status  
*C Betzold*
- e38** Response to: 'Postpartum breastfeeding status' by Betzold  
*A M Eudy, A M Siega-Riz, S M Engel, N Franceschini, A G Howard, M E B Clowse, M Petri*
- e39** 'Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study' by Moltó *et al*: still a long way to go in the assessment of patients with spondyloarthritis and concomitant fibromyalgia?  
*A Altobelli, R Scrivo, G Valesini*
- e40** Response to: ' "Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study" by Moltó *et al*: still a long way to go in the assessment of patients with spondyloarthritis and concomitant fibromyalgia?' by Altobelli *et al*  
*A Moltó, M Dougados*
- e41** Reference level of serum urate for clinically evident incident gout  
*X Chen, X Ding*
- e42** Response to: 'The reference levels of serum urate for clinically evident incident gout' by Chen and Ding  
*N Dalbeth, A Phipps-Green, C Frampton, T Neogi, W J Taylor, T R Merriman*
- e43** Response to: 'Statins in systemic lupus erythematosus' by Abud-Mendoza  
*H J I de Jong, T P van Staa, J W Cohen Tervaert*
- e44** Inconsistency between Danish incidence and prevalence data about psoriatic arthritis (P<sup>SA</sup>)  
*P Sewerin, A Hoyer, M Schneider, B Ostendorf, R Brinks*
- e45** Detection of myositis-specific antibodies: additional notes  
*M Mahler, M J Fritzler*